



PRESS RELEASE, March 3<sup>rd</sup>, 2022

## **Airbus and IUCT-Oncopole join forces to accelerate oncology research**

**Toulouse, 3 March 2022 - Airbus and IUCT-Oncopole have signed a two-year agreement to develop research projects of mutual interest, particularly in the field of artificial intelligence (AI) and data analysis.**

AI is growing rapidly and holds enormous potential for the future of medicine, especially in the detection and personalised treatment of specific cancers. This collaboration will focus on themes such as improving diagnostic techniques and monitoring the health of patients. The teams will link their networks with major research bodies to develop trusted, responsible, safe and explainable AI.

*"The ambition of this newly signed partnership is to bring together a world leader in aeronautics with a world-class leader centre in oncology to accelerate cancer research using AI. The treatment of cancer is a major cause that Airbus wishes to support by contributing to the development of digital technologies that are becoming increasingly important both in healthcare and research and aeronautics. This cooperation around digital platforms for data processing based on the latest technologies in terms of big data, the cloud and AI, should therefore allow the two parties to gain from each other's experience and advance innovation in each sector. We believe that we can learn from IUCT-Oncopole while helping it to further its advanced research in the fight against cancer, which remains a major challenge for healthcare in France and international"* said **Marc Hamy, VP Corporate Affairs of Airbus.**

Airbus has developed capabilities not only to monitor the status of aircraft fleets by processing data from sensors but also to extract information from images that could potentially be of interest to IUCT-Oncopole. In terms of innovation, AI technology is now paving the way for developments such as automatic in-flight refuelling from an A330 MRTT and the taxiing, take-off and landing of an A350 test aircraft in complete autonomy.

*"By pooling our expertise with that of the aerospace industry, we hope to accelerate the development of increasingly personalised medical innovations. Health is also a field where AI has been used for many years. Some of the technologies developed for medical applications could enrich the capabilities currently used in the aerospace sector,"* said **Prof. Jean-Pierre Delord, Director General of IUCT-Oncopole.**

Recent discoveries are now opening up new therapeutic prospects for preventing and curing cancers in an increasingly personalised way thanks to AI, such as a vaccine for cancer that has been undergoing a clinical trial at IUCT-Oncopole for over a year. Other projects with AI are being developed to model patient monitoring at home, to improve precision in radiotherapy, and to improve diagnosis through medical imaging and the characterisation of tumours on slides.

*"All this progress has been made possible thanks to the public/private partnership that we have developed over the last few years, and we are delighted to continue to ramp up our AI collaboration with the world leader in aeronautics,"* added **Professor Delord.**

**About Airbus**

Airbus is a world leader in aeronautics, space and related services. In 2019, the group reported a turnover of €70 billion, with a workforce of around 135,000. Airbus offers the most complete range of airliners available. In addition, Airbus is the European leader in mission, air-to-air refuelling, combat and transport aircraft. The company is also a leader in the space industry. Finally, Airbus manufactures the world's most efficient civil and military helicopters.

**About IUCT-Oncopole**

IUCT-Oncopole, a cancer care, research and training centre in Toulouse (France) combines the expertise of 1,800 professionals on a single site officially recognised as a Comprehensive Cancer Centre. It boasts several cutting-edge clinical facilities for the treatment of cancer with world-class research infrastructure located on an integrated campus that brings together public and private stakeholders, including industrial partners. IUCT-Oncopole treats more than 10,000 new patients each year, and more than one in eight patients are enrolled in clinical trials. It is comprised of the Claudius Régaud Institute and several teams from Toulouse University Hospital. [www.iuct-oncopole.fr](http://www.iuct-oncopole.fr)

**Press contact / IUCT- Oncopole**

Fleur de Lempdes - Communication Director  
06-34-53-31-70 [delempdes.fleur@iuct-oncopole.fr](mailto:delempdes.fleur@iuct-oncopole.fr)